Back to JHPCYView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting
View Full LandscapeDrug Information
Target Indication
KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting
Clinical Trial
NCT07232875Last updated: 7/21/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
JSKN003Phase 3
Advanced Solid Tumor
Irinotecan liposome、5-Fluorouracil、LeucovorinPhase 3
Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy
X0002 SprayPhase 3
KNEE OSTEOARTHRITIS
RocuroniumPhase 3
Neuromuscular Blockade
HRS-9190Phase 3
Neuromuscular Blockade
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts